AGM Post-Meeting Shareholder Engagement Update
Summary by AI BETAClose X
Oxford Nanopore Technologies plc
("Oxford Nanopore" or the "Company")
AGM Post-Meeting Shareholder Engagement Update
8 December 2025
In accordance with Provision 4 of the UK Corporate Governance Code, Oxford Nanopore Technologies plc (LSE: ONT) is providing an update to the statements made on 4 June 2025 in relation to the voting outcome of Resolution 12 at its 2025 Annual General Meeting ("AGM").
Following the AGM, the Company has undertaken an engagement exercise and invited feedback from its major shareholders to understand why certain shareholders were unable to support the resolution. The Board is grateful to those shareholders who engaged with this process.
Feedback received from shareholders has been consistent with the Board's focus on maximising the long-term potential of Oxford Nanopore. As previously announced, the Company continues to refine its strategic planning process to ensure it prioritises and executes on high-priority opportunities that best leverage the unique capabilities of Oxford Nanopore's technology. This will enable the Company to focus resources where it can create the greatest long-term value for stakeholders.
The appointment of Francis Van Parys as Chief Executive Officer brings extensive experience in scaling life-sciences businesses. Francis will lead the next phase of the commercial strategy and will work closely with the Board to deepen and strengthen the broader capability set across the management team to support the next phase of growth and deliver long-term value for all stakeholders.
-ENDS-
For further information please contact:
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 5 hours ago ASOS
- 5 hours ago MJ Gleeson
- 5 hours ago Rolls-Royce Holdings
- 6 hours ago Crest Nicholson Holdings
- 6 hours ago Naked Wines